Grifols (GIKLY) Operating Leases (2019 - 2025)
Grifols (GIKLY) reported Operating Leases of $1.1 billion for Q4 2025, up 2.98% on a YoY basis from $1.1 billion in Q4 2024, and up 2.98% quarter-over-quarter from $1.1 billion in Q4 2024.
Grifols (GIKLY) Operating Leases (2019 - 2025) Analysis & Trends
Grifols has reported Operating Leases for 7 years, with the latest figure at $1.1 billion in Q4 2025.
- For the quarter ending Q4 2025, Operating Leases rose 2.98% year-over-year to $1.1 billion; the trailing twelve-month figure through Dec 2025 stood at $1.1 billion (up 2.98% YoY), and the FY2025 full-year result was $1.1 billion, up 2.98% from the prior year.
- Operating Leases for Q4 2025 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Operating Leases was $1.1 billion in Q4 2025, with the low at $933.1 million in Q4 2022.
- Historically, Operating Leases has averaged $1.0 billion across 5 years, with a median of $1.1 billion in 2023.
- Annual changes were most pronounced in 2022 — Operating Leases declined 1.15% — and 2023, when it gained 15.79%.
- Grifols' Operating Leases stood at $944.0 million in 2021, then dropped by 1.15% to $933.1 million in 2022, then climbed by 15.79% to $1.1 billion in 2023, then advanced by 1.37% to $1.1 billion in 2024, then rose by 2.98% to $1.1 billion in 2025.
- The last three Operating Leases figures came in at $1.1 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Dec 31, 2022 | 933.11 Mn |
| Dec 31, 2021 | 943.96 Mn |
| Dec 31, 2020 | 823.70 Mn |
| Dec 31, 2019 | 770.71 Mn |